Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1830276rdf:typepubmed:Citationlld:pubmed
pubmed-article:1830276lifeskim:mentionsumls-concept:C0005821lld:lifeskim
pubmed-article:1830276lifeskim:mentionsumls-concept:C0006104lld:lifeskim
pubmed-article:1830276lifeskim:mentionsumls-concept:C0036751lld:lifeskim
pubmed-article:1830276lifeskim:mentionsumls-concept:C0008845lld:lifeskim
pubmed-article:1830276lifeskim:mentionsumls-concept:C0020934lld:lifeskim
pubmed-article:1830276lifeskim:mentionsumls-concept:C0070122lld:lifeskim
pubmed-article:1830276lifeskim:mentionsumls-concept:C0596902lld:lifeskim
pubmed-article:1830276lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:1830276lifeskim:mentionsumls-concept:C1510827lld:lifeskim
pubmed-article:1830276lifeskim:mentionsumls-concept:C1709059lld:lifeskim
pubmed-article:1830276pubmed:issue3lld:pubmed
pubmed-article:1830276pubmed:dateCreated1991-8-28lld:pubmed
pubmed-article:1830276pubmed:abstractTextThe dissociations of [3H]imipramine, [3H]paroxetine and [3H]citalopram from the 5-HT (serotonin 5-hydroxytryptamine) transporter were found to be markedly influenced by several drugs, although concentrations in the microM range were needed. Most of these drugs attenuated the dissociation rate, i.e. increased the affinity between the ligand and the binding site. A few increased the dissociation rate however. The binding of drugs to the affinity-modulating site was specific, although of low affinity and probably changing the conformation of the high-affinity binding site, thereby changing the fit between the ligand and the interacting amino acid side-chains. Although the drugs usually affected the dissociation rates of the three ligands in the same manner, there were some which had different effects on [3H]imipramine, [3H]paroxetine and [3H]citalopram. For example, 5-HT markedly attenuated the dissociation of [3H]imipramine, had a moderate effect on [3H]paroxetine and very little effect on [3H]citalopram dissociation. This indicates that the three ligands are bound to different domains on the 5-HT transporter. [3H]Citalopram dissociation from human brain and rat brain were differently affected by several drugs. Indalpine augmented the dissociation rate of the [3H]citalopram 5-HT transport complex in human brain but attenuated it in rat brain, thus revealing a species difference of the 5-HT transporter.lld:pubmed
pubmed-article:1830276pubmed:languageenglld:pubmed
pubmed-article:1830276pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830276pubmed:citationSubsetIMlld:pubmed
pubmed-article:1830276pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830276pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830276pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830276pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830276pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830276pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830276pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830276pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830276pubmed:statusMEDLINElld:pubmed
pubmed-article:1830276pubmed:monthMarlld:pubmed
pubmed-article:1830276pubmed:issn0014-2999lld:pubmed
pubmed-article:1830276pubmed:authorpubmed-author:MellerupE TETlld:pubmed
pubmed-article:1830276pubmed:authorpubmed-author:PlengePPlld:pubmed
pubmed-article:1830276pubmed:authorpubmed-author:LaursenHHlld:pubmed
pubmed-article:1830276pubmed:issnTypePrintlld:pubmed
pubmed-article:1830276pubmed:day25lld:pubmed
pubmed-article:1830276pubmed:volume206lld:pubmed
pubmed-article:1830276pubmed:ownerNLMlld:pubmed
pubmed-article:1830276pubmed:authorsCompleteYlld:pubmed
pubmed-article:1830276pubmed:pagination243-50lld:pubmed
pubmed-article:1830276pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1830276pubmed:meshHeadingpubmed-meshheading:1830276-...lld:pubmed
pubmed-article:1830276pubmed:meshHeadingpubmed-meshheading:1830276-...lld:pubmed
pubmed-article:1830276pubmed:meshHeadingpubmed-meshheading:1830276-...lld:pubmed
pubmed-article:1830276pubmed:meshHeadingpubmed-meshheading:1830276-...lld:pubmed
pubmed-article:1830276pubmed:meshHeadingpubmed-meshheading:1830276-...lld:pubmed
pubmed-article:1830276pubmed:meshHeadingpubmed-meshheading:1830276-...lld:pubmed
pubmed-article:1830276pubmed:meshHeadingpubmed-meshheading:1830276-...lld:pubmed
pubmed-article:1830276pubmed:meshHeadingpubmed-meshheading:1830276-...lld:pubmed
pubmed-article:1830276pubmed:meshHeadingpubmed-meshheading:1830276-...lld:pubmed
pubmed-article:1830276pubmed:meshHeadingpubmed-meshheading:1830276-...lld:pubmed
pubmed-article:1830276pubmed:meshHeadingpubmed-meshheading:1830276-...lld:pubmed
pubmed-article:1830276pubmed:meshHeadingpubmed-meshheading:1830276-...lld:pubmed
pubmed-article:1830276pubmed:meshHeadingpubmed-meshheading:1830276-...lld:pubmed
pubmed-article:1830276pubmed:meshHeadingpubmed-meshheading:1830276-...lld:pubmed
pubmed-article:1830276pubmed:year1991lld:pubmed
pubmed-article:1830276pubmed:articleTitleAffinity modulation of [3H]imipramine, [3H]paroxetine and [3H]citalopram binding to the 5-HT transporter from brain and platelets.lld:pubmed
pubmed-article:1830276pubmed:affiliationNeuropsychiatry Institute, University of Copenhagen, Rigshospitalet, Denmark.lld:pubmed
pubmed-article:1830276pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1830276pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1830276lld:pubmed